PE20121560A1 - Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana - Google Patents

Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana

Info

Publication number
PE20121560A1
PE20121560A1 PE2012000669A PE2012000669A PE20121560A1 PE 20121560 A1 PE20121560 A1 PE 20121560A1 PE 2012000669 A PE2012000669 A PE 2012000669A PE 2012000669 A PE2012000669 A PE 2012000669A PE 20121560 A1 PE20121560 A1 PE 20121560A1
Authority
PE
Peru
Prior art keywords
seq
sequence
antibodies against
humanized antibodies
human interleukin
Prior art date
Application number
PE2012000669A
Other languages
English (en)
Spanish (es)
Inventor
Roland Beckmann
Caroline Johnson-Leger
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41565648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121560(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of PE20121560A1 publication Critical patent/PE20121560A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2012000669A 2009-11-19 2010-11-12 Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana PE20121560A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09176525 2009-11-19
US26299809P 2009-11-20 2009-11-20

Publications (1)

Publication Number Publication Date
PE20121560A1 true PE20121560A1 (es) 2012-12-05

Family

ID=41565648

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000669A PE20121560A1 (es) 2009-11-19 2010-11-12 Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana

Country Status (20)

Country Link
US (1) US8545844B2 (https=)
EP (1) EP2512511B1 (https=)
JP (1) JP5818804B2 (https=)
KR (1) KR20120098783A (https=)
CN (1) CN102665759B (https=)
AU (1) AU2010321047B2 (https=)
BR (1) BR112012012003A2 (https=)
CA (1) CA2778864C (https=)
EA (1) EA021356B1 (https=)
EC (1) ECSP12011980A (https=)
ES (1) ES2531996T3 (https=)
IL (1) IL219740A0 (https=)
IN (1) IN2012DN03362A (https=)
MX (1) MX2012005791A (https=)
NZ (1) NZ599438A (https=)
PE (1) PE20121560A1 (https=)
PH (1) PH12012500924A1 (https=)
UA (1) UA105405C2 (https=)
WO (1) WO2011061119A1 (https=)
ZA (1) ZA201202793B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4898691B2 (ja) * 2004-10-22 2012-03-21 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
DK2686347T3 (en) 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
EP3137503A1 (en) * 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
WO2017157325A1 (zh) * 2016-03-18 2017-09-21 舒泰神（北京）生物制药股份有限公司 神经生长因子融合蛋白、制备方法及其用途
GB201612337D0 (en) * 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
EP3630182A4 (en) * 2017-05-24 2021-02-24 Development Center for Biotechnology HUMANIZED ANTIBODIES TO GLOBO H AND THEIR USE IN CANCER TREATMENT
WO2019000105A1 (en) 2017-06-30 2019-01-03 Zymeworks Inc. STABILIZED CHIMERIC FABES
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
CN119836287A (zh) * 2022-06-03 2025-04-15 里奥制药有限公司 Il-22r抗体的液体制剂
EP4704974A1 (en) 2023-03-08 2026-03-11 LEO Pharma A/S Il-22r antibody for use in treating atopic dermatitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
JP4898691B2 (ja) * 2004-10-22 2012-03-21 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
AU2006226060A1 (en) * 2005-03-25 2006-09-28 Glycart Biotechnology Ag Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function
EP1954719A2 (en) * 2005-12-02 2008-08-13 Genentech Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r

Also Published As

Publication number Publication date
CN102665759B (zh) 2015-09-30
US20120230990A1 (en) 2012-09-13
PH12012500924A1 (en) 2012-11-26
JP2013511267A (ja) 2013-04-04
ES2531996T3 (es) 2015-03-23
UA105405C2 (ru) 2014-05-12
JP5818804B2 (ja) 2015-11-18
WO2011061119A1 (en) 2011-05-26
IL219740A0 (en) 2012-07-31
EP2512511A1 (en) 2012-10-24
MX2012005791A (es) 2012-07-03
CA2778864A1 (en) 2011-05-26
KR20120098783A (ko) 2012-09-05
EP2512511B1 (en) 2015-01-07
AU2010321047B2 (en) 2016-06-09
ECSP12011980A (es) 2012-07-31
AU2010321047A1 (en) 2012-05-24
CA2778864C (en) 2017-06-27
EA021356B1 (ru) 2015-05-29
BR112012012003A2 (pt) 2016-11-29
CN102665759A (zh) 2012-09-12
IN2012DN03362A (https=) 2015-10-23
US8545844B2 (en) 2013-10-01
NZ599438A (en) 2013-12-20
ZA201202793B (en) 2013-06-26
EA201290360A1 (ru) 2012-11-30

Similar Documents

Publication Publication Date Title
PE20121560A1 (es) Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana
PE20142041A1 (es) Anticuerpos anti-il-36r
BR112013032899A2 (pt) anticorpos anti-axl e utilizações dos mesmos
PE20080036A1 (es) Anticuerpos humanos para la interleucina-13 (il13)
PE20131465A1 (es) Moleculas de union a 4-1 bb
AR073978A1 (es) Anticuerpos humanos de alta afinidad para el receptor il-4-humano
PE20141188A1 (es) Polipeptidos anticuerpos que antagonizan cd40
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
ES2570853T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20141162A1 (es) Anticuerpos anti-il-23
PE20170665A1 (es) Anticuerpos anti-tau humanizados
AR076564A1 (es) Anticuerpos humanizados de axl(receptor de tirosina quinasa)
CL2012000914A1 (es) Anticuerpos monoclonales que se unen especificamente a la region c-terminal de progastrina. uso para la preparacion de un medicamento util en el tratamiento de cancer colorectal.
BR112016011025A8 (pt) anticorpo humanizado anti calicreina-2.
HRP20191326T1 (hr) Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15)
BR112012021327B8 (pt) anticorpo monoclonal anti-her2 humanizado, método de preparação e uso do mesmo.
EA201290173A1 (ru) Антитела против эндоглина
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
NZ594682A (en) Fully human antibodies specific to cadm1
EA201490433A1 (ru) Новое антитело против ngf человека
JOP20190103A1 (ar) شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري
RU2014127287A (ru) Антитела, используемые для пассивной вакцинации против гриппа
PE20130192A1 (es) Anticuerpos il-25 humanizados
MX2013011414A (es) Novedoso anticuerpo anti-receptor de il-23 humano.

Legal Events

Date Code Title Description
FD Application declared void or lapsed